Informační systém MU
LITZMAN, Jiří, Tomáš FREIBERGER, Bodo GRIMBACHER, Benjamin GATHMANN, Uli SALZER, Tomáš PAVLÍK, Jiří VLČEK, Věra POSTRÁNECKÁ, Zita TRÁVNÍČKOVÁ and Vojtěch THON. Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency. CLINICAL AND EXPERIMENTAL IMMUNOLOGY. BLACKWELL PUBLISHING, 2008, vol. 153, No 3, p. 324-330. ISSN 0009-9104.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency
Name in Czech Polymorfismy MBL vedou u pacienůl s CVID ke vzniku bronchiektázií, ale ne jiných komplikací
Authors LITZMAN, Jiří, Tomáš FREIBERGER, Bodo GRIMBACHER, Benjamin GATHMANN, Uli SALZER, Tomáš PAVLÍK, Jiří VLČEK, Věra POSTRÁNECKÁ, Zita TRÁVNÍČKOVÁ and Vojtěch THON.
Edition CLINICAL AND EXPERIMENTAL IMMUNOLOGY, BLACKWELL PUBLISHING, 2008, 0009-9104.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.853
Organization unit Faculty of Medicine
UT WoS 000258376200003
Keywords (in Czech) CVID, komplement, MBL
Keywords in English common variable immunodeficiency; complement; lung disease
Tags common variable immunodeficiency, complement, lung disease
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Jiří Litzman, CSc., učo 403. Changed: 2/4/2010 08:01.
Abstract
Mannose-binding lectin (MBL), activating protein of the lectin pathway of the complement system, is an important component of the non-specific immune response. MBL2 gene polymorphisms, both in the coding and promoter regions, lead to low or deficient serum MBL levels. Low serum MBL levels were shown to be associated with serious infectious complications, mainly in patients in whom other non-specific immune system barriers were disturbed (granulocytopenia, cystic fibrosis). We have analysed two promoter (-550 and -221) and three exon (codons 52, 54 and 57) MBL2 polymorphisms in a total of 94 patients with common variable immunodeficiency (CVID) from two immunodeficiency centres. Low-producing genotypes were associated with the presence of bronchiectasis (P = 0.009), lung fibrosis (P = 0.037) and also with respiratory insufficiency (P = 0.029). We could not demonstrate any association of MBL deficiency with age at onset of clinical symptoms, age at diagnosis, the number of pneumonias before diagnosis or serum immunoglobulin (Ig)G, IgA and IgM levels before initiation of Ig treatment. No association with emphysema development was observed, such as with lung function test abnormalities. No effect of MBL2 genotypes on the presence of diarrhoea, granuloma formation, lymphadenopathy, splenomegaly, frequency of respiratory tract infection or the number of antibiotic courses of the patients was observed. Our study suggests that low MBL-producing genotypes predispose to bronchiectasis formation, and also fibrosis and respiratory insufficiency development, but have no effect on other complications in CVID patients.
Abstract (in Czech)
Polymorfismy MBL vedou u pacienůl s CVID ke vzniku bronchiektázií, ale ne jiných komplikací
Links
NR9035, research and development projectName: Specifická protilátková odpověď u pacientů s poruchami imunity
NR9192, research and development projectName: Screening mutací a polymorfismů v genu pro neonatální Fc receptor u pacientů s primárními poruchami tvorby protilátek
Displayed: 30/4/2024 12:47